Study on BW12C and Mitomycin C for Colorectal Cancer
Author Information
Author(s): Propper D J, Levitt N C, O'Byrne K, Braybrooke J P, Talbot D C, Ganesan T S, Thompson C H, Rajagopalan B, Littlewood T J, Dixon R M, Harris A L
Primary Institution: ICRF Medical Oncology Unit, Churchill Hospital, Headington, Oxford, OX3 7LJ, UK
Hypothesis
Can the combination of BW12C and mitomycin C improve treatment outcomes in advanced colorectal cancer?
Conclusion
The combination of BW12C and mitomycin C is not effective for treating 5-FU-resistant colorectal cancer.
Supporting Evidence
- BW12C stabilizes oxyhaemoglobin, causing a left-shift of the oxygen saturation curve.
- The activity of mitomycin C is enhanced by hypoxia.
- The predominant toxicities were mild and did not exceed CTC grade 2.
- Liver31P magnetic resonance spectroscopy showed no changes consistent with tissue hypoxia.
Takeaway
Doctors tested a new treatment for cancer, but it didn't work as hoped for patients who didn't respond to other treatments.
Methodology
17 patients with metastatic colorectal cancer received BW12C and mitomycin C, with specific dosing and monitoring.
Limitations
The study's findings may be affected by drug resistance rather than the treatment's ineffectiveness.
Participant Demographics
Patients had metastatic colorectal cancer resistant to 5-fluorouracil.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website